Author of

• 12837

  +

  P3.22 - Poster Session 3 - Epidemiology, Etiology (ID 168)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Prevention & Epidemiology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12847

    +

    P3.22-010 - Advanced Non-Small Cell Lung Cancer (NSCLC-AD) in patients under 50 - a new reality (ID 3404)

    09:30 - 09:30  |  Author(s): L. Fernandes
    • Abstract

    Background
    The incidence of NSCLC in young patients increases annually. Our objective is to characterize this specific population

    Methods
    Retrospective study of 61 consecutive NSCLC-AD cases in patients under 50 years old, diagnosed between 2001 and 2011. Clinical data, histology, Performance Status (PS), therapy and overall survival (OS) were evaluated.

    Results
    Of all the patients 70.5% were men, mean age 44.7 ± 4.12 years, most of them smokers (55.7%) with a Performance Status (PS) of 1 (83.6%), 2 (9.8%) or 3 (6.6%). Comorbidities were found in 42.6% of patients. The most frequent histology was adenocarcinoma (55.7%) followed by squamous cell (39.4%) and large cell (4.9%). Metastasis in 1, 2 or 3 organs were found in 49.2%, 27.9% and 22.9% respectively. Excluding two patients that are still alive (49.5 and 65.3 months after initial diagnosis), the global OS was 12.4 months. All patients with PS 3 were smokers with comorbidities, had more than 2 sites of metastization and underwent best supportive care only. Mean OS of this group was 0.7 months. Only 1 patient with PS 2 showed comorbidities and they were all submitted to 1[st] line chemotherapy with "platinum-based doublets". No 2[nd] line therapy was initiated and mean OS of this group was 4.7 months. In the PS 1 group (51 patients), 43.1% showed at least 1 comorbidity and 56.9% had >1 metastasized organ. The mean OS of this group was 10.8 months. All patients underwent 1[st] line chemotherapy – options were "platinum-based doublets" (50 patients) and Erlotinib (1 patient). Second line therapy was done in 60.8% (31) of these patients (Pemetrexed in 14 patients, Docetaxel in 11 patients and Erlotinib in 6 patients), and 3[rd] line in 35.5% (11) – options were Erlotinib (9 patients), Pemetrexed and Carboplantin+Vinorelbine (1 patient each). Two patients started 4[th] line therapy (3.9%) with Pemetrexed. OS for different therapeutic lines in this group (patients that underwent only one line of therapy, 2 lines or 3 lines) were respectively 5.8 months, 11.45 months and 29.2 months.

    Conclusion
    In our study, young patients with NSCLC present in advanced stages with important comorbidities and have an overall prognosis similar to the literature. Stronger physical reserve may allow several therapeutic lines to be completed in a significant number of cases.